Bristol Myers Squibb (BMY) has seen its stock rise over 20% in the past year, despite projections of declining sales in 2026. The company anticipates revenue will drop to between $46 billion and $47.5 billion, down from $48.2 billion in 2025, largely due to slowing sales from its legacy portfolio and concerns over the upcoming patent expiration of its key drug, Eliquis. However, Bristol’s growth portfolio is showing promise, with sales increasing from $22.6 billion in 2024 to $26.4 billion in 2025, which helps mitigate the overall revenue decline.
For investors, Bristol Myers offers a compelling mix of stability and income, characterized by a low beta of 0.2, indicating minimal volatility compared to the broader market. Additionally, the stock boasts a robust dividend yield of 4.2%, supported by 17 consecutive years of annual increases. As the market anticipates the Q1 2026 earnings report on April 30, the combination of low volatility and consistent dividends positions Bristol as an attractive option for long-term investors.
Source: fool.com